Comparing Xenetic Biosciences (XBIO) and Its Rivals

Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Xenetic Biosciences to similar businesses based on the strength of its dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.

Insider and Institutional Ownership

15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Xenetic Biosciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Xenetic Biosciences -123.72% -58.97% -49.54%
Xenetic Biosciences Competitors -12,519.20% -215.47% -31.42%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Xenetic Biosciences and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xenetic Biosciences 1 0 0 0 1.00
Xenetic Biosciences Competitors 9959 15361 45766 1602 2.54

As a group, “Biotechnology” companies have a potential upside of 114.70%. Given Xenetic Biosciences’ peers stronger consensus rating and higher probable upside, analysts plainly believe Xenetic Biosciences has less favorable growth aspects than its peers.

Valuation & Earnings

This table compares Xenetic Biosciences and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Xenetic Biosciences $2.98 million -$2.68 million -0.90
Xenetic Biosciences Competitors $730.63 million $9.19 million -17.98

Xenetic Biosciences’ peers have higher revenue and earnings than Xenetic Biosciences. Xenetic Biosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Xenetic Biosciences has a beta of 2.36, meaning that its stock price is 136% more volatile than the S&P 500. Comparatively, Xenetic Biosciences’ peers have a beta of -1.84, meaning that their average stock price is 284% less volatile than the S&P 500.

Summary

Xenetic Biosciences peers beat Xenetic Biosciences on 9 of the 13 factors compared.

About Xenetic Biosciences

(Get Free Report)

Xenetic Biosciences, Inc. is a biotechnology company focused on developing immuno-oncology treatments. Its XCART platform is designed to create personalized CAR T-cell therapies that recognize tumor-specific antigens on B-cell lymphomas, with the goal of targeting cancer cells while limiting effects on healthy cells. The company’s earlier work included PolyXen, a drug-delivery platform based on polysialic acid that was designed to extend the time biologic medicines remain in the body. Xenetic’s current stated focus is advancing its XCART technology and related product candidates.

Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.